Application of the Traditional Chinese Medicine Monomer Rhamnosin in the Preparation of Drugs for the Treatment of Leukemia
The traditional Chinese medicine monomer rhamnin inhibits the proliferation of leukemia cells and induces apoptosis, combined with cytarabine, the problem of chemotherapy resistance of leukemia is solved, and safe and efficient leukemia treatment effect is achieved.
CN119326748BActive Publication Date: 2025-08-08DONGGUAN PEOPLES HOSPITAL
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202411060224.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2025-08-08
- Estimated Expiration
- 2044-08-02
AI Technical Summary
Technical Problem
There are problems with chemotherapy and targeted drug resistance in the current treatment of leukemia, and there is a lack of new chemotherapy treatment drugs with high safety and low toxicity and side effects.
Method used
The traditional Chinese medicine monomer rhamnocin or its solvate, hydrate or salt is used to inhibit the PI3K-AKT signaling pathway, inhibit the proliferation of leukemia cells and induce apoptosis, and combine cytarabine to enhance the efficacy.
Benefits of technology
It significantly inhibits the growth of various leukemia cells, prolongs the survival of tumor-bearing mice, has high anti-tumor activity and has few side effects.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides the use of a traditional Chinese medicine monomer, rhamnosine, or a solvate, hydrate, or salt thereof, in the preparation of a drug for treating or alleviating leukemia. The present invention explores the anti-tumor activity of rhamnosine from multiple levels, including in vitro and in vivo levels. Experiments have shown that the traditional Chinese medicine monomer, rhamnosine, can inhibit the proliferation of leukemia cell lines, induce cell apoptosis, and enhance the effect of cytarabine in inhibiting leukemia; in vivo, rhamnosine can inhibit the growth of leukemia subcutaneous transplanted tumors and prolong the survival of tumor-bearing mice. Further experiments revealed the biological mechanism by which rhamnosine inhibits leukemia proliferation and promotes apoptosis by regulating the PI3K‑AKT signaling pathway, indicating that it has certain prospects in the treatment of leukemia.
Need to check novelty before this filing date? Find Prior Art